ProtoKinetix Inc (PKTX)

[MIKE2OO5]

Few more weeks!

July 9, 2019 9:00 AM
PROTOKINETIX REACHES MID-POINT OF 3RD STAGE OF RETINAL CELL REPLACEMENT THERAPY TESTING AT UBC

MARIETTA, Ohio

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) has reached the mid-point of 3rd stage of testing in retinal cell replacement therapy at the University of British Columbia. Functionality testing on experimental models three months post-transplant show encouraging results. We anticipate results from six-month post-transplant to be available within the next 4-5 weeks. The study includes two experimental models over a longer period of time to test whether the AAGP® treated cells continue to develop and mature into retinal cells to potentially restore vision in humans. The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.